EU/3/01/068: Orphan designation for the treatment of multiple myeloma

Thalidomide

Table of contents

Overview

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in December 2008 on request of the Sponsor.

On 19 December 2001, orphan designation (EU/3/01/068) was granted by the European Commission to Kendle International Limited, United Kingdom, for thalidomide for the treatment of multiple myeloma.

Key facts

Active substance
Thalidomide
Intended use
Treatment of multiple myeloma
Orphan designation status
Withdrawn
EU designation number
EU/3/01/068
Date of designation
19/12/2001
Sponsor
Kendle International Ltd
Angel House
24 Station Road
Ely, Cambs CB7 4BS
United Kingdom
Telephone: +44 13 53 66 97 89
Telefax: +44 13 53 66 84 73
E-mail: info.ely@kendle.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating